Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires AML Preclinical Asset from Bridge Medicines October 8, 2024
Cartherics raises over $15 Million in oversubscribed private financing round to advance cell therapy programs October 8, 2024
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance DOC1021 into a Ph 2 Clinical Trial October 8, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® October 8, 2024
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical October 8, 2024
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in RCC October 8, 2024
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor’s Portfolio of next-gen CDK inhibitors for Treating Breast Cancer October 2, 2024
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362 October 2, 2024
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy October 2, 2024
Prime Medicine and BMS to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies October 2, 2024
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer October 2, 2024
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Gen Immunotherapeutics Discovery September 25, 2024
GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers September 24, 2024
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Clinical-Stage T-Cell Engagers September 18, 2024
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies September 18, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors September 18, 2024
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers September 18, 2024
Scancell and PharmaJet to use Stratis® IM Needle-free delivery System for SCIB1/iSCIB1+ vaccine for Advanced Melanoma September 17, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs in solid tumors through Clinical Development September 10, 2024
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody September 10, 2024
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors September 10, 2024
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA September 10, 2024
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer September 10, 2024
